Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Mol Cancer Res. 2020 Jun 8;18(9):1278–1289. doi: 10.1158/1541-7786.MCR-20-0046

Figure 2. Model is the predominant determinant of EMT signature.

Figure 2

RNA-seq data showing the fold change in expression of EMT markers in (A) All GEMM derived tissues compared to all allograft-derived tissues, or (B) Metastasis-specific gene expression from GEMM models compared to allograft models. (C) qRT-PCR data showing epithelial (blue) or mesenchymal (red) EMT marker expression in spleen metastases and liver metastases that were subsequently grown in primary culture.